B
ALNY icon

Barings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Barings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,661
Closed -$242K – 191
2022
Q2 		$242K Buy
+1,661
New +$236K 0.01% 277
2014
Q3 		– Sell
-21,100
Closed -$1.33M – 949
2014
Q2 		$1.33M Buy
+21,100
New +$1.25M 0.04% 424

Other funds holding ALNY

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Barings's ALNY Position: Q3 2022 in Review

Barings sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 1,661 shares — an estimated $242K sold.

Barings first reported a position in ALNY in Q2 2014 and held it in 2 quarters. The position peaked at $1.33M in Q2 2014. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Barings reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Barings sold 1,661 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $242K.
  • Barings first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Barings's Alnylam Pharmaceuticals position peaked at $1.33M in Q2 2014.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Barings's 13F filing for Q3 2022, filed 14 Nov 2022.